Used in targeted cancer therapy, particularly for breast and prostate cancers that express prolactin receptors. This monoclonal antibody blocks prolactin signaling, which can inhibit tumor growth and proliferation. It is also employed in diagnostic applications to detect prolactin receptor expression in tissue samples, aiding in patient selection for receptor-targeted treatments. Investigated in clinical trials for its potential to enhance efficacy when combined with other oncology therapeutics.